secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-263617
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Q3 net revenue $38.2M, acute care +67% YoY, FY guidance reaffirmed
------------------------------------------------------------------------

- Q3 net revenue $38.2M (+16.5% YoY); YTD $114.3M.
- ZYNRELEF net revenue $9.3M (+49% YoY); APONVIE $3.0M (+173% YoY).
- FY 2025 guidance reaffirmed: net revenue $153-163M, adj. EBITDA $9-13M.
- J-code for ZYNRELEF effective Oct 1, 2025; VAN transition complete.
- Cash and investments $55.5M as of Sept 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000119312525263617/0001193125-25-263617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000119312525263617/hrtx-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-263617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer